Aker BioMarine ASA (OSL:AKBM)
Norway
· Delayed Price · Currency is NOK | Market Cap | 8.49B |
| Revenue (ttm) | 2.20B |
| Net Income (ttm) | -229.84M |
| Shares Out | 87.70M |
| EPS (ttm) | -2.62 |
| PE Ratio | n/a |
| Forward PE | 41.52 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,769 |
| Average Volume | 10,908 |
| Open | 100.00 |
| Previous Close | 100.20 |
| Day's Range | 96.80 - 100.00 |
| 52-Week Range | 49.55 - 118.00 |
| Beta | 0.29 |
| RSI | 36.36 |
| Earnings Date | Apr 30, 2026 |
About Aker BioMarine ASA
Aker BioMarine ASA, a biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. The company operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business. The Human Health Ingredients segment sells B2B krill oil supplements for humans under the Superba Krill brand; supplements for brain health under the LYSOVETA brand; and marine-origin DHA omega-3 from microalgae under the Revervia brand name, as well as advanced phospholipid technology under P... [Read more]
News
World’s largest krill harvester at centre of row over ‘blue tick’ sustainability label
Aker QRILL is facing criticism of its fishery management amid calls by environmentalists for curbs on Antarctic fishing of the keystone species Environmental groups have objected to the recommendation...
Aker BioMarine ASA (FRA:1PG) Q4 2025 Earnings Call Highlights: Strong Growth in Human Health ...
Aker BioMarine ASA (FRA:1PG) Q4 2025 Earnings Call Highlights: Strong Growth in Human Health Ingredients Amidst Consumer Health Challenges
Q4 2025 Aker Biomarine ASA Earnings Call Transcript
Q4 2025 Aker Biomarine ASA Earnings Call Transcript
Aker BioMarine ASA Earnings Call Transcript: Q4 2025
Q4 2025 saw 6% revenue and 66% EBITDA growth, led by a 28% surge in Human Health Ingredients, while consumer health declined 8%. Strategic focus is on maximizing Human Health Ingredients value, with strong guidance for 2026 and ongoing capacity expansion.
Aker BioMarine ASA (OSL:AKBM) Q4 2025 Earnings Report Preview: What To Look For
Aker BioMarine ASA (OSL:AKBM) Q4 2025 Earnings Report Preview: What To Look For
Aker BioMarine ASA (STU:1PG) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...
Aker BioMarine ASA (STU:1PG) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges
Q3 2025 Aker Biomarine ASA Earnings Call Transcript
Q3 2025 Aker Biomarine ASA Earnings Call Transcript
Aker BioMarine ASA Earnings Call Transcript: Q3 2025
Q2 and Q3 2025 saw double-digit revenue and EBITDA growth, led by Human Health Ingredients and Consumer Health Products, with improved margins and operational leverage. The company is addressing production challenges, expanding in Asia, and expects continued growth, while managing risks from tariffs and restructuring.
Aker BioMarine ASA (OSL:AKBM) Q3 2025 Earnings Report Preview: What To Expect
Aker BioMarine ASA (OSL:AKBM) Q3 2025 Earnings Report Preview: What To Expect
Aker BioMarine ASA (FRA:1PG) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...
Aker BioMarine ASA (FRA:1PG) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid Operational Challenges
Q2 2025 Aker Biomarine ASA Earnings Call Transcript
Q2 2025 Aker Biomarine ASA Earnings Call Transcript
Aker BioMarine ASA Earnings Call Transcript: Q2 2025
Q2 2025 saw 12% revenue growth and 41% higher adjusted EBITDA, led by strong human health and consumer health segments. Operational leverage, cost reallocation, and product innovation drove margin gains, while a $15 million impairment was taken on the protein plant due to tariff uncertainty.
Aker BioMarine ASA Earnings Call Transcript: Q1 2025
Q1 2025 saw 5% revenue growth and a 59% rise in adjusted EBITDA, led by strong human health segment performance and cost control. New clinical trials, retail partnerships, and market expansion underpin a positive outlook, with risks from tariffs and market timing mitigated.
Aker BioMarine ASA Earnings Call Transcript: Q4 2024
Q4 2024 saw 7% revenue growth and a near tripling of EBITDA, led by Human Health Ingredients, while Consumer Health Products declined but is expected to rebound in 2025. Restructuring and cost optimization are ongoing, with strong global demand and new product launches supporting future growth.
What To Expect From Aker BioMarine ASA (OSL:AKBM) Q4 2024 Earnings
What To Expect From Aker BioMarine ASA (OSL:AKBM) Q4 2024 Earnings
Aker BioMarine ASA Earnings Call Transcript: Q3 2024
Q3 2024 saw the closure of the Feed Ingredients sale, a $214M net gain, and a $373M dividend. Human Health Ingredients and Emerging Business segments drove EBITDA growth, while cost optimization and refinancing strengthened the balance sheet.
Aker BioMarine ASA Earnings Call Transcript: Q2 2024
Q2 saw the $590M sale of the Feed Ingredient business, with remaining operations focusing on human health and nutrition. Revenue grew 6% to $94M, EBITDA rose 35%, and an extraordinary dividend is planned post-transaction. Human Health Ingredient and international channels showed strong growth.